Novo Nordisk’s New Wegovy Trial Could Mean Smaller Pills, Fewer Side Effects
Novo Nordisk just started a trial that could change how doctors prescribe. The question is simple. Can a smaller…
-
-
Novo Nordisk Taps Omnicom to Lead US Marketing for Ozempic and Wegovy
Novo Nordisk has a new media partner. The drugmaker just named Omnicom as its agency of record for US…
-
Dual GLP-1 and glucagon Receptor Drugs in Metabolic Care
Dr. Mazen Noureddin views dual GLP-1 and glucagon receptor drugs as a major step forward in metabolic medicine. He…
-
Novo Nordisk Price Target Rises to $80 as Oral Wegovy Surpasses 3 Million Prescriptions
Novo Nordisk received an upgraded price target of $80, while market analysts assigned the stock a Modest Buy rating….
-
How GLP-1 Weight-Loss Drugs Are Forcing Restaurants to Rethink Their Menus
Weight-loss drugs like Ozempic and Wegovy aren’t just changing waistlines, they are changing how Americans eat out. According to…
-
Samsung Biologics Offers $1.8 Billion to Acquire PolyPeptide
Samsung Biologics has offered to buy PolyPeptide in an all-cash deal worth approximately $1.8 billion, which translates to $55.17…
-
Clinical Management of Wegovy Storage Protocols
Proper storage of injectable semaglutide products directly affects medication strength and patient safety. Wegovy, a glucagon-like peptide-1 receptor agonist,…
-
GLP-1 Weight-Loss Medications See Unprecedented Surge in US Usage
Interest in GLP-1 drugs for shedding pounds has exploded across the country. The trend line alone tells a compelling…
-
America’s $6 Trillion Medical Bill: How Weight Loss Injections Are Reshaping What the Country Pays for Healthcare
Americans dropped $5.7 trillion on medical care in 2025. That number is hard to wrap your head around. Moreover,…
-
Novo Nordisk Discloses Cybersecurity Breach Amid Push for Oral Wegovy Approval in China
Novo Nordisk is dealing with a major security headache after hackers broke into their systems and stole private patient…
